Genetic studies reveal an unexpected negative regulatory role for jak2 in thrombopoiesis

Blood

Volumn 124, Issue 14, 2014, Pages 2280-2284

  Meyer, Sara C ^a   Keller, Matthew D ^a   Woods, Brittany A ^a,b   Lafave, Lindsay M ^a,b   Bastian, Lennart ^a   Kleppe, Maria ^a   Bhagwat, Neha ^a,b   Marubayashi, Sachie ^a   Levine, Ross L ^a,b  

^a Human Oncology and Pathogenesis Program   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; JANUS KINASE 2; STAT PROTEIN; STEM CELL ANTIGEN 1; STEM CELL FACTOR; THROMBOPOIETIN; JAK2 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BLOOD CELL COUNT; CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; GENE DELETION; GENETIC ANALYSIS; INTERNALIZATION; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEM CELL; STEM CELL EXPANSION; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; TURNOVER TIME; ANIMAL; BLOOD; CROSS BREEDING; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD PLATELETS; CROSSES, GENETIC; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATOPOIETIC STEM CELLS; JANUS KINASE 2; MEGAKARYOCYTES; MICE; SIGNAL TRANSDUCTION; STEM CELLS; THROMBOCYTOSIS; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 84907683139     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-560441     Document Type: Article

References (31)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
3. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
4. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
5. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5): 459-468.
6. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
7. Verstovsek S, Mesa RA, Gotlib J, et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9): 799-807.
8. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.
9. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013; 6(1):79.
10. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs. 2013;22(6):687-699.
11. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74(2):227-236.
12. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409.
13. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395.
14. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40(1):52-57.
15. Park SO, Wamsley HL, Bae K, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS ONE. 2013;8(3):e59675.
16. Grisouard J, Hao-Shen H, Dirnhofer S, Wagner KU, Skoda RC. Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia. Haematologica. 2014; 99(4):e52-e54.
17. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood. 2009;113(8):1778-1785.
18. Tiedt R, Coers J, Ziegler S, et al. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009; 113(8):1768-1777.
19. Ng AP, Kauppi M, Metcalf D, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci USA. 2014; 111(16):5884-5889.
20. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
21. Pronk CJ, Rossi DJ, Ma°nsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442.
22. Tomer A. Human marrow megakaryocyte differentiation: multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood. 2004; 104(9):2722-2727.
23. Calaminus SD, Guitart AV, Sinclair A, et al. Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. [published correction appears in PLoS ONE. 2013;8(5)]. PLoS ONE. 2012;7(12):e51361.
24. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem. 1999; 274(19):13480-13484.
25. Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232-236.
26. Shin JY, Hu W, Naramura M, Park CY. High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. J Exp Med. 2014;211(2):217-231.
27. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mplmediated binding to platelets. Blood. 1996;87(6): 2154-2161.
28. Shivdasani RA, Fielder P, Keller GA, Orkin SH, de Sauvage FJ. Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice. Blood. 1997;90(5): 1821-1827.
29. Koppikar P, Abdel-Wahab O, Hedvat C, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010; 115(14):2919-2927.
30. Kraus M, Wang Y, Aleksandrowicz D, et al. Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera. PLoS ONE. 2012;7(5):e37207.
31. Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell quiescence via PF4 secretion [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21):3.